Revenue
$60.4B
Gross Margin
+81.7%
Operating Margin
+23.7%
Net Margin
+17.2%
Income statement waterfall for AstraZeneca (AZN) — TTM through Q1 2026
Net income: $10.4B
Margin breakdown for AstraZeneca (AZN) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Revenue | $60.4B | $60.4B |
| Cost of Revenue | -$11.1B | $49.4B |
| Gross Profit | $49.4B | $49.4B |
| Operating Expenses | -$35.1B | $14.3B |
| Operating Income | $14.3B | $14.3B |
| Other Income / Expense | -$1.4B | $12.9B |
| Pre-tax Income | $12.9B | $12.9B |
| Income Tax | -$2.52B | $10.4B |
| Net Income | $10.4B | $10.4B |
- Revenue$60.4B
- Cost of Revenue-$11.1B
- Gross Profit$49.4B
- Operating Expenses-$35.1B
- Operating Income$14.3B
- Other Income / Expense-$1.4B
- Pre-tax Income$12.9B
- Income Tax-$2.52B
- Net Income$10.4B
Want to see what changed vs last year?Profit Bridge
Frequently asked questions
Data & methodology
AstraZeneca (AZN) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Cash Flow
Forecast & Valuation
Operations
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement
Capital Return
- Buybacks0.14% TTM
- Dividend Profile1.89% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History3 splits
How this company returns cash to shareholders — buybacks, dividends, and stock splits.